MedTrace Logo

Synuclein-One Study

NCT04700722 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 428

Last updated 2024-01-03

No results posted yet for this study

Summary

The Synuclein-One Study will be evaluating α-synuclein in patients with Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies and Pure Autonomic Failure. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.

Conditions

Interventions

DIAGNOSTIC_TEST

Skin Biopsy

Test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein, define sensitivity and specificity of skin biopsy detection of phosphorylated α-synuclein deposition for the diagnosis of synucleinopathies and to differentiate between the synucleinopathies by quantitative measurement of phosphorylated α-synuclein with skin biopsies.

Sponsors & Collaborators

  • CND Life Sciences

    lead OTHER

Principal Investigators

  • Todd Levine, MD · CND Life Sciences: www.cndlifesciences.com

Eligibility

Min Age
40 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-04
Primary Completion
2022-12-14
Completion
2023-11-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04700722 on ClinicalTrials.gov